0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in the pivotal Phase 2 ALPHA3 trial in first-line consolidation for large B-cell lymphoma. Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 The company said the study is the first designed to test whether early, measurable residual disease-guided consolidation with cema-cel can prevent recurrence in LBCL, and that it is enrolling across more than 60 activated clinical trial sites in academic and community cancer centers, including sites outside the United States. An interim futility analysis is planned for April 2026 and will compare MRD clearance rates and early safety outcomes between the cema-cel arm and observation. The company also highlighted progress in autoimmune disease with ALLO-329, a dual CD19/CD70 AlloCAR T candidate that uses its Dagger technology to reduce or potentially eliminate conventional lymph [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in the pivotal Phase 2 ALPHA3 trial in first-line consolidation for large B-cell lymphoma. Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 The company said the study is the first designed to test whether early, measurable residual disease-guided consolidation with cema-cel can prevent recurrence in LBCL, and that it is enrolling across more than 60 activated clinical trial sites in academic and community cancer centers, including sites outside the United States. An interim futility analysis is planned for April 2026 and will compare MRD clearance rates and early safety outcomes between the cema-cel arm and observation. The company also highlighted progress in autoimmune disease with ALLO-329, a dual CD19/CD70 AlloCAR T candidate that uses its Dagger technology to reduce or potentially eliminate conventional lymph [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS